David A Driver

US Patent:

6342372, Jan 29, 2002

Filed:

Jul 8, 1999

Appl. No.:

09/350399

Inventors:

John M. Polo - San Diego CA
David A. Driver - San Diego CA

Assignee:

Chiron Corporation - Emeryville CA

International Classification:

C12N 516

US Classification:

435 691, 435455, 536 2372, 536 232, 536 241

Abstract:

The present invention provides compositions and methods for utilizing recombinant alphavirus vectors. Also disclosed are compositions and methods for making and utilizing eukaryotic layered vector initiation systems.

US Patent:

6376236, Apr 23, 2002

Filed:

Jan 22, 1999

Appl. No.:

09/236140

Inventors:

John M. Polo - San Diego CA
Carlos E. Ibanez - San Diego CA
David A. Driver - San Diego CA

Assignee:

Chiron Corporation - Emeryville CA

International Classification:

C12N 1563

US Classification:

4353201

Abstract:

Disclosed are recombinant alphavirus particles comprising a) an alphavirus vector construct which directs the expression of a heterologous nucleic acid molecule; b) a capsid protein; and c) an envelope glycoprotein from a virus different from said alphavirus vector.

US Patent:

7572628, Aug 11, 2009

Filed:

Jan 16, 2003

Appl. No.:

10/346880

Inventors:

John M. Polo - San Diego CA, US
Carlos E. Ibanez - San Diego CA, US
Stephen M. W. Chang - San Diego CA, US
Douglas J. Jolly - Leucadia CA, US
David A. Driver - San Diego CA, US
Barbara A. Belli - San Diego CA, US

Assignee:

Novartis Vaccines and Diagnostics, Inc. - Emeryville CA

International Classification:

C12N 15/63
C12N 15/85
A61K 48/00
C07H 21/04

US Classification:

4353201, 435325, 514 44

Abstract:

The present invention provides compositions and methods for utilizing recombinant alphavirus vectors. Also disclosed are compositions and methods for making and utilizing eukaryotic layered vector initiation systems.

US Patent:

7977091, Jul 12, 2011

Filed:

Aug 10, 2009

Appl. No.:

12/538494

Inventors:

John M Polo - San Diego CA, US
Carlos E Ibanez - San Diego CA, US
Stephen M. W. Chang - San Diego CA, US
Douglas J Jolly - Leucadia CA, US
David A Driver - San Diego CA, US
Barbara A Belli - San Diego CA, US

Assignee:

Novartis Vaccines & Diagnostics, Inc. - Emeryville CA

International Classification:

C12N 15/63
C12Q 1/68

US Classification:

4353201, 435 6

Abstract:

The present disclosure provides compositions and methods for utilizing recombinant alphavirus vectors. Also disclosed are compositions and methods for making and utilizing eukaryotic layered vector initiation systems.

US Patent:

8541369, Sep 24, 2013

Filed:

Sep 25, 2012

Appl. No.:

13/626308

Inventors:

David Albert Driver - Solana Beach CA, US
Ryan James Darling - Fishers IN, US
Maigorzata Donata Gonciarz - Indianapolis IN, US
Radmila Micanovic - Indianapolis IN, US

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

A61K 38/18

US Classification:

514 91

Abstract:

This present invention relates to pharmacologically potent and/or stable variants of human fibroblast growth factor 21 (FGF21), pharmaceutical compositions comprising FGF21 variants, and methods for treating type 2 diabetes, obesity, dyslipidemia, or metabolic syndrome, or any combination thereof, using such variants.

US Patent:

20040029278, Feb 12, 2004

Filed:

May 17, 2002

Appl. No.:

10/150407

Inventors:

Thomas Dubensky - Rancho Sante Fe CA, US
John Polo - San Diego CA, US
Carlos Ibanez - San Diego CA, US
Stephen Chang - San Diego CA, US
Douglas Jolly - Leucadia CA, US
David Driver - San Diego CA, US
Barbara Belli - San Diego CA, US

Assignee:

Chiron Corporation

International Classification:

C12N015/861
C12N015/86

US Classification:

435/456000, 435/320100, 435/325000

Abstract:

The present invention provides compositions and methods for utilizing recombinant alphavirus vectors. Also disclosed are compositions and methods for making and utilizing eukaryotic layered vector initiation systems.

US Patent:

20050026161, Feb 3, 2005

Filed:

Nov 3, 2003

Appl. No.:

10/701347

Inventors:

Edward Jablonski - Escondido CA, US
David Driver - Solana Beach CA, US
Thomas Adams - Rancho Santa Fe CA, US

International Classification:

C12Q001/68

US Classification:

435006000

Abstract:

The present invention is directed to labeling antibodies with DNA in a convenient kit format for the purpose of producing and utilizing nucleic acid detection immunoassays. The process comprises treating a reporter antibody with a chemically activated strand of DNA, which serves as a template for any DNA amplification system. The reporter antibody-DNA conjugate is used to form a complex with corresponding antigen. The complex can be detected by the production of multiple copies of the DNA template. The kit may also provide an activated DNA sequence to label a capture antibody. The DNA conjugated to the capture antibody is modified to contain a high affinity binding ligand for the purpose of coating a solid support. The coated solid support functions to capture the immune complex containing reporter antibody in a sandwich assay format. The DNA sequence of the capture antibody may also have properties providing for the detachment of the complex from the solid support.

US Patent:

20130324460, Dec 5, 2013

Filed:

Aug 13, 2013

Appl. No.:

13/965243

Inventors:

David Albert DRIVER - Solana Beach CA, US
Ryan James DARLING - Fishers IN, US
Malgorzata Donata GONCIARZ - Indianapolis IN, US
Radmila MICANOVIC - Indianapolis IN, US

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

C07K 14/50

US Classification:

514 48, 530399, 514 91, 514 69, 514 74

Abstract:

This present invention relates to pharmacologically potent and/or stable variants of human fibroblast growth factor 21 (FGF21), pharmaceutical compositions comprising FGF21 variants, and methods for treating type 2 diabetes, obesity, dyslipidemia, or metabolic syndrome, or any combination thereof, using such variants.